Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today the latest efficacy and safety updates from the Phase 1/2 trial of SAR443579/IPH6101 (SAR’579), a CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE). The results were presented at the European Hematology Association 2024 Congress in Madrid, Spain. SAR’579, developed in collaboration with Sanofi under the ANKET® platform, demonstrated promising clinical efficacy and a favorable safety profile in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS).
Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma, expressed optimism about SAR’579’s progress, noting its transition to Phase 2 trials and potential to address significant unmet needs in blood cancer treatment. The study included 59 patients across various dose levels, with encouraging responses observed at the 1 mg/kg weekly dose, including durable complete responses in several AML patients. SAR’579 was generally well tolerated up to 6 mg/kg weekly doses, informing dose selection for Phase 2 development.
Peter Adamson, Global Development Head, Oncology at Sanofi, highlighted ongoing efforts to explore SAR’579’s potential in leukemia treatment, emphasizing future data disclosures at scientific forums. The collaboration leverages Innate’s ANKET® platform, designed to develop multi-specific NK cell engagers, representing a novel approach to enhancing anti-cancer immunity.
Innate Pharma’s collaboration with Sanofi, initiated in 2016, focuses on advancing SAR443579/IPH6101 and SAR445514/IPH6401 under licensing agreements that could yield substantial milestone payments and royalties. The partnership underscores Innate’s commitment to advancing innovative cancer therapies.
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation NK cell engagers targeting cancer.
Innate Pharma and Sanofi collaborate to develop innovative NK cell engagers, leveraging Innate’s technology to engage NK cells through NKp46 and CD16 receptors, aiming to eliminate tumor cells.
